NDAORALTABLET3 Generics Approved
Approved
Jan 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
IRA Negotiated
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FARXIGA (dapagliflozin) is an oral small-molecule SGLT2 inhibitor approved in 2014 for type 2 diabetes and heart failure indications. It works by inhibiting sodium-glucose cotransporter 2 in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. The drug has expanded significantly beyond its initial indication into cardiology, treating both diabetic and non-diabetic heart failure patients.
$4.3BPart D
PeakGrowing
15.0 years to LOEPeak lifecycle product with $4.3B annual spending and 917 linked roles indicates robust commercial infrastructure, though IRA price negotiation signals margin compression and team efficiency pressures ahead.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
Started Sep 2026
2,800 enrolled
Renal Insufficiency, Chronic
Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin
Started Aug 2026
10 enrolled
Kidney Failure
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
Started Jul 2026
800 enrolled
Type 2 Diabetes Mellitus
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
Started Jul 2026
2,000 enrolled
Type 2 Diabetes Mellitus
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
Started Jul 2026
900 enrolled
Type 2 Diabetes MellitusType 2 Diabetes With Chronic Kidney Disease
Worked on FARXIGA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.